Soleil Securities
http://www.soleilgroup.com/index.shtmlSoleil Securities provides equity research for institutional investors.
-
Soleil Lifts Price Target on Sequenom (SQNM) from $8 to $10
-
Notable Analyst Rating Changes 08/04: LEAP, BKS, MET, SQNM Upgraded; BHI, DOW, AEP, ARNA Downgraded
-
Soleil Securities Upgrades Sequenom (SQNM) to Buy
-
Notable Analyst Rating Changes 06/11: SQNM, SVVS, BMY, X Upgraded; LGF, AGU, WAG, THO Downgraded
-
Notable Analyst Rating Changes 03/23: SKS, BIDU, SQNM, SAP, FLEX Upgraded; ARAY, SYNA, AFL, AGU Downgraded
-
Soleil Securities Reiterates a 'Hold' Rating on Sequenom (SQNM); Lowers PT
-
Analyst Round-Up: Sequenom (SQNM); Numerous Downgrades Following Delay
-
Notable Analyst Rating Changes 4/30: OXPS, SNY, LAMR Upgraded; SQNM, GT, ITRI Downgraded
-
Soleil Securities Downgrades Sequenom (SQNM) to Hold
-
Soleil Securities Downgrades Sequenom (SQNM) to Hold
-
Soleil Securities Initiates Coverage on Sequenom (SQNM) with a Buy, Top Pick in Med-Tech
